Download MendeleyDiscovery of Novel 3-Quinoline Carboxamides as Potent, Selective and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (Atm) Kinase.
Degorce, S.L., Barlaam, B., Cadogan, E., Dishington, A.P., Ducray, R., Glossop, S.C., Hassall, L.A., Lach, F., Lau, A., Mcguire, T.M., Nowak, T., Ouvry, G., Pike, K.G., Thomason, A.G.(2016) J Med Chem 59: 6281
- PubMed: 27259031
- DOI: https://doi.org/10.1021/acs.jmedchem.6b00519
- Primary Citation of Related Structures:
5G55 - PubMed Abstract:
A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridinyl]-4-{[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]amino}-3-quinolinecarboxamide (72) and 7-fluoro-6-[6-(methoxymethyl)pyridin-3-yl]-4-{[(1S)-1-(1-methyl-1H-pyrazol-3-yl)ethyl]amino}quinoline-3-carboxamide (74) as potent and highly selective ATM inhibitors with overall ADME properties suitable for oral administration. 72 and 74 constitute excellent oral tools to probe ATM inhibition in vivo. Efficacy in combination with the DSB-inducing agent irinotecan was observed in a disease relevant model.
Organizational Affiliation:
Oncology Innovative Medicines Unit, AstraZeneca , Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.
